Get the Stockscreener App
3.08
0.65%
-0.02
Alto Neuroscience Inc stock is traded at $3.08, with a volume of 49,294.
It is down -0.65% in the last 24 hours and up +35.09% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$3.10
Open:
$3.05
24h Volume:
49,294
Relative Volume:
0.21
Market Cap:
$83.38M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-1.4286
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
+0.33%
1M Performance:
+35.09%
6M Performance:
-15.62%
1Y Performance:
-65.28%
1-Day Range:
$3.05
$3.0898
1-Week Range:
$3.00
$3.12
52-Week Range:
$1.60
$15.04
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
3.08 | 83.11M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.64 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.31 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) should contact The Gross Law Firm about pending Class ActionANRO - Morningstar
Real time alert setup for Alto Neuroscience Inc. performanceMarket Downturn Defense Strategy Analysis - Newser
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Alto Neuroscience, Inc. (ANRO) Investors of September 19, 2025 Deadline - ACCESS Newswire
Levi & Korsinsky Urges Alto Neuroscience, Inc. (ANRO) Shareholders to Act Before Lead Plaintiff Deadline September 19, 2025 - ACCESS Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain OfficersANRO - PR Newswire
Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors - GlobeNewswire
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Why Alto Neuroscience Inc. is moving todayReliable Setup Screener with Low Risk - Newser
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - Morningstar
Alto Neuroscience Inc. Crosses 200 Day MA — Signal or NoiseCapital Protection Trading Strategies Gain Interest - beatles.ru
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. LawsuitANRO - MarketScreener
Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - PR Newswire
Real time pattern detection on Alto Neuroscience Inc. stockTrading Watchlist with Real Time Filters - Newser
Why Alto Neuroscience Inc. stock attracts strong analyst attentionMonthly Trade Result and Signal Summary - Newser
Quant Tools Rank Alto Neuroscience Inc. as High Risk High RewardInvestment Playbook for Growing Markets Shared - beatles.ru
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit - PR Newswire
Alto Neuroscience, Inc. Sued for Securities Law Violations - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary DutyContact the DJS Law Group to Discuss Your Rights – ANRO - The Globe and Mail
ANRO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors Urged to Contact Levi & Korsinsky for Information Before September 19, 2025Alto Neuroscience, Inc. (ANRO) - TradingView
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. LawsuitANRO - PR Newswire
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT - GlobeNewswire
Tools to assess Alto Neuroscience Inc.’s risk profileFree Capital Protection Trading Strategies - Newser
Why is Alto Neuroscience Inc. stock attracting strong analyst attentionAchieve rapid portfolio appreciation today - Jammu Links News
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What analysts say about Alto Neuroscience Inc. stockStay informed with daily expert analysis - Jammu Links News
Alto Neuroscience Inc. Stock Analysis and ForecastBuild wealth with professional market analysis - Jammu Links News
ANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
What is the risk reward ratio of investing in Alto Neuroscience Inc. stockUnlock daily market insights for better trades - jammulinksnews.com
What institutional investors are buying Alto Neuroscience Inc. stockUnstoppable investment returns - Jammu Links News
What are analysts’ price targets for Alto Neuroscience Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
Bragar Eagel & Squire, P.C. Is Reminds Investors of Class - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO - FinancialContent
Class Action Filed Against Alto Neuroscience, Inc. (ANRO) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Can technical indicators confirm Alto Neuroscience Inc.’s reversalFree Early Entry Tips With Low Risk Zone - Newser
Class Action Filed Against Alto Neuroscience, Inc. (ANRO) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025ANRO - ACCESS Newswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto - GlobeNewswire
Best data tools to analyze Alto Neuroscience Inc. stockPortfolio Review Summary with Five-Year Outlook - Newser
Alto Neuroscience Got Sued Over Failed Depression Drug—Here’s What You Should Know - TradingView
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Alto Neuroscience, Inc. Stockholders with Large Losses Should Contact Shareholder Rights Law Firm Robbins LLP for Information on Leading the ANRO Class Action - Morningstar
Shareholders that lost money on Alto Neuroscience, Inc. - GlobeNewswire
ALTO NEUROSCIENCE, INC. (NYSE: ANRO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Alto Neuroscience, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Does Alto Neuroscience Inc. fit your quant trading modelTrade Ideas Based on Fundamental Metrics - Newser
Analyzing recovery setups for Alto Neuroscience Inc. investorsFree Multi-Bagger Potential Stock Forecast Tools - Newser
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Shareholders of Class Action Lawsuit And September 19, 2025 Deadline - ACCESS Newswire
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):